What is the practical use of 18F-fluorocholine positron emission tomography–computed tomography as an anatomic and functional test in hyperparathyroidism?
This systematic review of 16 studies found that 18F-fluorocholine positron emission tomography–computed tomography has high sensitivity, specificity, positive predictive value, and diagnostic accuracy compared with first-line tests, where concomitant thyroid disease or ectopic glands may decrease such indices. It is a second-line test when the results of ultrasonography and sestamibi scans are negative or discordant.
18F-fluorocholine positron emission tomography–computed tomography could be useful when there is clinical suspicion of hyperplasia, multiple lesions, persistent or recurrent hyperparathyroidism, small or ectopic adenomas, or normocalcemic hyperparathyroidism.
Identifying parathyroid glands correctly before a surgical procedure is essential to perform minimally invasive surgery. First-line tests with discordant or negative results underscore the need for more accurate imaging tests, thus decreasing the requirement for bilateral neck exploration or reintervention.
To review the available evidence to determine positive predictive value, negative predictive value, sensitivity, and specificity in clinical cases in which 18F-fluorocholine positron emission tomography–computed tomography (PET/CT) could be useful as a method to locate the lesions, and the benefits and controversial aspects of the method.
A search was conducted using the PubMed Central and Cochrane Library databases for studies published in English from July 26, 2014, to November 30, 2018, using the search terms 18 choline, 18F choline, 18F-choline, 18 fluorocholine PET CT, hyperparathyroidism, primary hyperparathyroidism, secondary hyperparathyroidism, tertiary hyperparathyroidism, persistent hyperparathyroidism, recurrent hyperparathyroidism, ectopic hyperparathyroidism, and parathyroid adenoma. Other inclusion criteria were reporting at least 1 of the following measurements: negative or positive predictive value, sensitivity, and specificity of 18F-fluorocholine PET/CT in the diagnosis of hyperparathyroidism (HPT). Exclusion criteria were language other than English, use of a tracer other than 18F-fluorocholine, reports of a single case, and studies not related to HPT. The Oxford Centre classifications for levels of evidence were used.
Sixteen studies fulfilled the inclusion criteria, comprising a total of 619 patients. Selected studies included 10 prospective cohort studies, 5 retrospective cohort studies, and 1 case series. Of the subtypes of HPT diagnosed using 18F-fluorocholine PET/CT, 579 were primary HPT, 22 were secondary HPT, 1 was tertiary HPT, and 7 were associated with multiple endocrine neoplasia type I. Pathologically, the neoplasms comprised 459 adenomas, 59 hyperplasia, and 19 double adenomas.
Conclusions and Relevance
18F-fluorcholine PET/CT may be indicated when results of first-line tests are negative or discordant and in challenging clinical situations where locating the source of HPT is difficult.
Boccalatte LA, Higuera F, Gómez NL, et al. Usefulness of 18F-Fluorocholine Positron Emission Tomography–Computed Tomography in Locating Lesions in Hyperparathyroidism: A Systematic Review. JAMA Otolaryngol Head Neck Surg. Published online May 30, 2019145(8):743–750. doi:10.1001/jamaoto.2019.0574
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: